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ORIGINAL RESEARCH ARTICLE Open Access
How Health Care Providers Can Use Digital Health
Technologies to Inform Human Papillomavirus (HPV)
Decision Making and Promote the HPV Vaccine Uptake
Among Adolescents and Young Adults
Versie Johnson-Mallard,1,* Gabrielle Darville,2 Rebeccah Mercado,3 Charkarra Anderson-Lewis,4 and Jann MacInnes5
Abstract
High-risk stains of human papillomavirus (HPV) is linked to causing cancer, is highly prevalent, and has increased
incidence among adolescents and young adults. However, vaccination rates are low. Health care provider rec-
ommendation is the biggest influencer toward vaccine uptake. Since more health care providers are using digital
health technologies in their medical practices, this study investigated the feasibility of technology to increase
informed decision making. A convenience sample of 210 students completed an online survey. Participants
were 18–25 years of age (88%), female (85%), Caucasian (60%), and never been diagnosed with HPV (92.9%).
Overwhelmingly, participants owned a smartphone (98.9%) and used mobile apps for health/health tracking
(65.5%). However, only 29.3% indicated that they received text messages from their health care provider. Digital
health technology can be a cost-effective way for increasing HPV knowledge, removing barriers, and increasing
vaccine uptake. Health care providers should explore using various platforms to empower their health care de-
cision making.
Keywords: HPV; preventive health; vaccine
Introduction
Human papillomavirus (HPV) infection is the most
common sexually transmitted infection (STI) in the
United States and is responsible for 99% of all cervical
cancer cases worldwide.1,2 HPV is also associated with
other forms of cancer such as anal, oropharyngeal, vag-
inal, vulvar, and penile.3,4 Although vaccines are avail-
able to reduce the risk of infection by several of the
most prevalent strains of this virus, immunization
rates continue to remain low. The HPV vaccine is a
two-dose regimen, a shift from a three-dose regimen
in 2016, offering protection to those not completing
the HPV vaccine series. Specifically, a two-dose regi-
men is recommended for girls and boys starting the
HPV series at ages 9 through 14 years, three doses re-
main for boys and girls starting the HPV series at ages
15 through 26 years. In October 2018, the Food and
Drug Administration (FDA) expanded the approved use
of the HPV vaccine (Gardasil-9) to include women and
men ages 27 through 45 years.5 In data from the 2016
National Immunization Survey, only 65% of adolescent
females and 56% of males initiated the two- or three-
dose vaccine series with 50% of adolescent females
and 38% of males completing the series.6 Not only
are these rates lower than the Healthy People 2020
goal of 80% vaccination, but there is also a distinct
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difference in the number of adolescent males being vac-
cinated compared with females.7,8 This disparity may
not only be due, in part, to the 5-year lag in the Centers
for Disease Control and Prevention (CDC)’s recom-
mendation for the HPV vaccine in adolescent males
(2011) compared with adolescent females (2006), but
it may also be attributed to the ‘‘feminization of
HPV’’ as a women’s problem emphasizing the need
for frequent and early recommendations by health
care providers to parents of adolescent males in partic-
ular.9
Current literature highlights the importance of
health care providers in increasing vaccine uptake
with the most common correlate of HPV vaccination
acceptance being a provider’s recommendation and
the most commonly cited reason for nonvaccination
being a lack of provider recommendation.10 In a na-
tionally representative survey of parents, those parents
with adolescent males more frequently expressed being
unsure or not likely to have their child vaccinated
against HPV, compared with parents of adolescent fe-
males, primarily due to a lack of provider recommen-
dation or knowledge. If providers regularly inform
patients and parents about the benefits of the HPV vac-
cine as a cancer prevention, particularly those who are
unsure, as well as distribute reminders to patients who
are due for vaccination based on recommended immu-
nization schedules, there is an opportunity to improve
HPV vaccine uptake among adolescents.11,12
One way providers can better inform patients and
parents as well as provide reminders of upcoming im-
munizations is through the use of technology. Text
messaging and smartphone applications (apps) pres-
ent two areas in new media with potential for use as
vaccine uptake interventions. Both technologies are
highly accessible and popular worldwide, and their
usage is more evenly distributed across divisions of
race, class, and international borders compared with
other devices and services such as desktop and laptop
computers and home broadband.13–15
Current literature indicates an increase in the use of
text messaging and apps as mobile health interven-
tions, with evidence that these methods have succeeded
in reducing missed appointments, educating adoles-
cents about sexual health, and tracking patient infor-
mation. However, very little existing research has
examined the application of these technologies to inter-
ventions for HPV vaccine uptake and completion of
the two- or three-dose series, demonstrating the need
for further inquiry within this area.
Literature Review
HPV pathology and epidemiology
HPV refers to a group of over 150 related types of a
DNA tumor virus that causes abnormal growth and ac-
cumulation of epithelial tissue in skin and mucous
membranes,1,16 More than 40 types of HPV infect the
human genital tract and can be transmitted through di-
rect sexual contact, including oral, vaginal, and anal
sex. Each of these sexually transmitted types of HPV
falls into one of two categories: nononcogenic or low-
risk strains that can cause the formation of skin warts
in the anogenital area and the oncogenic or high-risk
strains that can cause cervical, anal, oropharyngeal,
vaginal, vulvar, and penile cancers.17
HPV is responsible for *90% of all cases of genital
warts, 99% of all cervical cancers, 95% of all anal can-
cers, and 70% of all oropharyngeal cancers world-
wide.1,2,17 HPV is the most common STI in the
United States, with *79 million Americans currently
infected and 14 million becoming newly infected every
year. The global prevalence of HPV infection in
women without cervical abnormalities is *11% to
12%, with higher regional rates in sub-Saharan Africa,
Eastern Europe, and Latin America.18 The worldwide
prevalence of HPV infection among males receives lit-
tle to no coverage in the current literature.
HPV vaccination
To reduce the risk of HPV infection and its potential
health effects, the U.S. (CDC) recommends that indi-
viduals use latex condoms during sexual activity, attend
routine screenings for cervical cancer if applicable, and
receive HPV vaccinations.1 The CDC currently recom-
mends that all children ages 11 to 12 receive two doses of
an HPV vaccine 6 to 12 months apart; ‘‘catch-up’’ vacci-
nation is also recommended on a three-dose schedule for
females up to age 26 years, males up to age 21 years,
transgender adults up to age 26 years, and young adults
with immunocompromising conditions such as HIV/
AIDS up to age 26 years. Three noninfectious HPV vac-
cines are currently approved for use by the U.S. FDA.5
The bivalent vaccine Cervarix (2vHPV, manufac-
tured by GlaxoSmithKline in Rixensart, Belgium) tar-
gets HPV types 16 and 18, the oncogenic strains
responsible for the majority of all HPV-related cancers.
The quadrivalent vaccine Gardasil (4vHPV, manufac-
tured by Merck and Co, Inc., in Whitehouse Station,
NJ) adds protection from strains 6 and 11, which are re-
sponsible for genital warts; its nonavalent counterpart,
Gardasil-9 (9vHPV), includes additional protection
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from types 31, 33, 45, 52, and 58.19 In 2015, *62.8% of
females and 49.8% of males in the United States had re-
ceived at least one dose of an HPV vaccine; only 41.9%
of females and 28.1% of males had attained complete
vaccine adherence with three or more doses.20 An esti-
mated 59 million women worldwide have received at
least one dose, making up 1.7% of the global female
population, while 47 million—1.4%—have received
the complete course of the vaccine.21 Data on interna-
tional male HPV vaccine coverage are absent from cur-
rently available literature.
Theoretical application
Digital health technologies, as a cue to action within the
health belief model (HBM) as seen in Figure 1, can im-
pact the health decision making among adolescent and
newly transitioned college students.22 This is especially
important when communicating messages about HPV
and the HPV vaccine because research has shown that
adolescents and college students alike are unaware of
their risk of contracting the disease and how the
HPV virus can be contracted. Because of this, the pur-
pose of this research study is to determine how health
care providers can utilize digital health technologies
(such as the internet, mobile phones, short message
service [SMS] text messages, and mobile apps) to in-
crease individual risk perception of the HPV virus, in-
crease awareness about the HPV vaccine, overcome
barriers to the HPV vaccine, and help adolescents and
young adults make informed decisions to get the HPV
vaccine. The research questions that guided the research
agenda are as follows:
 R01: How knowledgeable are college students of
the HPV virus?
 R02: What are the beliefs and attitudes of college
students toward the HPV vaccine?
 R03: What barriers exist for college students pre-
venting uptake of the HPV vaccine?
 R04: What digital health platforms (channels)
would college students prefer to receive informa-
tion about the risk of the HPV virus?
Methodology
Sample
The study was conducted among both male and female
undergraduate and graduate students at a large public
university in North Florida. Similar to other interven-
tions focused on college students, they were selected
as the study participants because of their constant expo-
sure to the internet and technology. As Patel et al.23 ex-
plains, research should find ways ‘‘to implement HPV
interventions via technologies acceptable to college stu-
dents (e.g., text messaging, e-mail, social networking
FIG. 1. Health belief model.
Johnson-Mallard, et al.; BioResearch Open Access 2019, 8.1
http://online.liebertpub.com/doi/10.1089/biores.2018.0051
86
media) etc.’’ as it could improve the efficacy of inter-
ventions aimed at this population.23 Quantitative data
on the survey included questions that asked about de-
mographic characteristics, sexual health behaviors,
knowledge of HPV, barriers to HPV uptake, and digital
health technology practices.
Procedure
After Institutional Review Board approval was obtained,
faculty of undergraduate and graduate courses in the
Department of Health Education and Behavior were
contacted and data collection was conducted with this
convenience sample. Because of the descriptive nature
of the survey, no inclusion and exclusion criteria were
established. The survey was implemented using online
software. Before data collection, the survey was pilot
tested with a sample of undergraduate and graduate stu-
dents (n = 81). Feedback provided from this sample was
used to revise the survey for data collection, which was
conducted over a period of 6 months.
Study participants were provided with an electronic
link of the survey from their faculty. This link also in-
cluded an inform consent page, which provided a dis-
claimer informing them of the sexual nature of the
questions and listed on campus resources should they
need to discuss any concerns they may have. Once con-
sent was electronically obtained, participants were pro-
moted to begin the survey. No incentives were offered
by researchers for participating in the survey, however,
faculty of the courses could offer extra credit if they
chose to do so.
Survey instrument
Using validated and reliable scales found in HPV risk
perception research11,24–26 and questions about tech-
nology use and digital health practices from Pew
Research Center’s Mobile Health, Health Tracking
and Social Media Update Surveys,27–29 researchers de-
veloped a 54-item questionnaire, the Digital Health
Solutions for Informed Decision Survey. Participants
could differ in their number of responses per question.
Multiple responses were possible. Participants could
also decline to answer any question to which they did
not want to answer.
Apart from demographical information, students
provided answers to items that asked about their sexual
activity behavior, sexual intercourse engagement, cur-
rent sexual activity, number of sexual partners in the
past 30 days, total number of lifetime partners, type
of sexual activity ever engaged in, contraception use,
condom use, gender of all sexual partners, history of
sexually transmitted disease (STD) or HPV diagno-
sis, and HPV vaccination practices. Students answered
questions concerning HPV knowledge, sources used to
obtain HPV information, and beliefs regarding HPV.
Their beliefs as it relates to cancer and HPV vaccination
were measured, for this population used the Health
Belief Scale, which included dimensions on four con-
structs of the HBM (perceived severity, perceived sus-
ceptibility, perceived benefits, and perceived barriers).
Students were also provided a list of frequently cited
barriers throughout HPV literature and asked to select
all that apply to them. Lastly, items included questions
that also asked about smartphone ownership, smart
phone usage, tracking devices/application use, types
of health apps, digital health information practices, so-
cial media channel frequency use and access routes,
SMS health messages, preference of channel to receive
information, comfortableness using these digital tech-
nologies for HPV and HPV vaccine information, and
interest in receiving information through SMS text
message or mobile apps. Within this questionnaire,
there were several questions included, an ‘‘other’’ re-
sponse item, to allow participants the opportunity to
provide information if the best response was not listed.
Data analysis
Descriptive statistics (means and frequencies) were cal-
culated for the measures. Because researchers used pre-
viously validated and reliable scale items identified in
literature, Cronbach’ alpha was not calculated for the
purpose of this research study.
Results
Although 210 participants contributed to this research
study, survey responses varied for each section of
questions as some questions included missing data.
All results collected are reported in Tables 1–8. Male
and female study participants completed the self-
administered survey (Table 1). Demographic charac-
teristics identified that the majority of the population
was 18–25 years old (n = 147; 88%), female (n = 143;
85.6%), not of Hispanic origin (n = 136; 64.8%),
White/Caucasian (n = 126; 60%), upperclassman and
seniors (n = 103; 61.6%), went to school fulltime
(n = 154; 92.2%), were Florida residents (n = 161;
97.6%), and had private health insurance through
their parents (n = 122; 73.1%). The majority of the sur-
vey respondents were citizens of the United States
(Table 1).
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Before answering specific questions related to sexual
practices and behavior, HPV risk perception, HPV vac-
cine beliefs and knowledge, and technology behavior,
study participants were asked whether the HPV vac-
cine should be mandatory for children ages 9–12
years. Overwhelmingly, 74% of students (n = 144) out
of 195 total responses indicated that the vaccine should
be mandatory for adolescent-aged children. Reasons
for making HPV vaccinations mandatory at that age
are highlighted in the direct quotes noted below:
Participant 1: ‘‘The age range was chosen because it is
a time before a child’s first encounter of sexual in-
tercourse and exposure to HPV. With that being the
case, it serves as a great preventative measure for
children and I think that it would only benefit the
population if it is mandatory. However, I do feel that
there should be exceptions to the requirement for
those who would not benefit from the vaccine.’’
Participant 2: ‘‘Because the age kids are still in the
routine of getting vaccinated.’’
Participant 3: ‘‘To children it is just another shot,
however it can save their lives in the future. Even
if the children do not grow up to be sexually ac-
tive, it is at least a precaution.’’
Participant 4: ‘‘I think it should be mandatory
because taking the vaccine during the best im-
mune response time would likely have a signif-
icant impact on public health outcomes, and
although one concern parents may have is that it
might encourage an earlier age of initiation for
sexual activity, I don’t think those two factors
are necessarily related since young children
don’t need to know that the vaccine is for an
STI. Being protected from one STI should not be
an enabling factor for unsafe sex if there is
proper sex education involved (which there al-
ways should be).’’
Table 1. Demographic Variables, Frequency, and Percent
Descriptive variables Frequency (n) Valid percent (%) Descriptive variables Frequency (n) Valid percent (%)
Age (years) Classification
18–25 147 88 Freshman (1st year) 33 19.8
26–34 14 8.4 Sophomore (2nd year) 21 12.6
35–54 4 2.0 Upperclassman (3rd year) 61 36.5
45–54 1 0.6 Senior (4th + year) 42 25.1
55–64 1 0.6 Graduate student 10 6.0
Total 167 100 Total 167 100
Gender Student status
Male 24 14.4 Part-time 13 7.8
Female 143 85.6 Full-time 154 92.2
Total 167 100 Total 167 100
*Ethnicity (check all that apply) Health insurance
Not of Hispanic, Latino (a) or Spanish Origin 136 81 Private through parents 122 73.1
Puerto Rican 7 4.0 Work or University Insurance 21 12.6
Cuban 4 2.0 Public or other insurance 16 9.6
Another Hispanic, Latino, or Spanish Origin 15 8.9 None or not sure 8 4.8
Do not wish to respond 7 4.0 Total 167 100
Total 169 100 Nationality/citizenship
*Race (check all that apply)
Black or African American 14 8
White or Caucasian 126 75 Canada 1 0.6
Asian Indian 5 3 China 2 1.2
Chinese 4 2 Honduras 1 0.6
Filipino 9 5 Malaysia 1 0.6
Korean 4 2 Pakistan 1 0.6
Vietnamese 3 2 Peru 1 0.6
Do not wish to respond 6 4 Romania 1 0.6
Total 171 100 United Kingdom 1 0.6
Residency (where do you currently live?) United States 157 94
California 1 0.6 Vietnam 1 0.6
Florida 161 97.6 Total 167 100
Georgia 1 0.6
New York 1 0.6
Texas 1 0.6
Total 165 100
*Note: One or more categories could be selected.




Responses to STD/HPV vaccine and sexual history
behaviors can be found in Tables 1 and 2. Majority
of the sample was reproductive age non-Hispanic
women (Table 1). Greater than 90% of the study sam-
ple self-reported no history of STDs and no history of
HPV (Table 2). Greater than 62% received three doses
of HPV vaccine. Table 3 highlights the level of HPV
awareness and knowledge among our study popula-
tion. Areas of concern, and questions answered incor-
rectly included: you get HPV for life, and condoms
protect against HPV infection. Safety appears to be a
concern for about half of the study population, 51%
do not have confidence that the HPV vaccine is safe,
and 47% believe the HPV vaccine is harmful (Table 4).
Study participants in our sample were queried in greater
detail about their beliefs and were asked to indicate their
level of agreement concerning 14 statements related to
key barriers to HPV vaccine uptake. Lack of informa-
tion and knowledge about HPV or HPV vaccine was
identified as a barrier to HPV uptake (Table 5).
Information concerning study sample current digital
health technology practices were queried (Table 6).
Most used smartphones to access social media several
times a day (Table 7). Facebook was the highest social
media trend (*76%) followed by Instagram (68%)
and LinkedIn not being used often (7%; Table 6).
When asked about the preferred digital health tech-
nologies to communicate about HPV risk and vac-
cine, the preferred platform was identified as
internet or online website. Receiving text messages
about HPV was not popular, only *29% were inter-
ested in receiving health-related text. Comfort with
using various health channels to receive HPV vaccine
information was low for social network sites (22%),
and digital gaming (13.5%; Table 8).
Discussion
Evidence was explored to support strategies to facilitate
digital health technologies aimed at increasing risk
perception of the HPV virus and awareness of the
HPV vaccine. The preferred method of communication
by college students to communicate HPV risk and
Table 2. Sexually Transmitted Diseases and Human























Yes, I have started the vaccine series
(three
shots) and intend to complete it
14 7.3
Yes I have started the vaccine and DO
NOT
intend to complete it
6 3.1




Received doses of the HPV vaccine
1 dose 7 3.7
2 doses 16 8.4
All 3 doses 117 61.6
None 40 21.1




HPV, human papillomavirus; STD, sexually transmitted disease.
Table 3. Human Papillomavirus Knowledge Among College Students
HPV knowledge Total Correct answer (n) Valid percentage (%)
1. People with certain HPV types always develop health problems. (False) 185 136 73.5
2. Women can get HPV. (True) 185 184 99.5
3. Condoms effectively protect against HPV infection. (False) 185 82 44.3
4. HPV may spread from person to person by sexual intercourse. (True) 185 185 100
5. Males may be infected with HPV and not know it. (True) 185 180 97.3
6. HPV infection can be cured with antibiotics. (False) 185 155 83.8
7. Men can get HPV. (True) 185 181 97.8
8. If you get HPV, you will have HPV for life. (False) 185 49 26.5
9. Females may be infected with HPV and not know it. (True) 185 183 98.9
10. A person can get HPV by having sex. (True) 185 185 100
11. HPV infection among women is rare. (False) 185 177 95.7
12. Condoms always protect you from HPV. (False) 185 177 95.7
13. HPV may be spread from person to person through oral sex. (True) 184 169 91.8
14. HPV infection among men is rare. (False) 184 145 78.8
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vaccine was internet or online websites. Strategy, use of
the internet, mobile phones, SMS test messages, and
mobile apps to help disseminate evidence-based HPV
and HPV vaccination information to adolescents and
college students was explored. Currently, most college
students reported not receiving text messages from
health care providers as updated to health care or mes-
sages on the HPV virus. In this study, electronic sur-
veys explored preferred digital health technologies in
addition to HPV knowledge, individual risk percep-
tion, and awareness of the HPV vaccine. The HPV vac-
cine was approved for use in boys in 2011 and girls in
2006. Knowledge and awareness of HPV and HPV vac-
cine were significant and high among our study partic-
ipants. The majority of the study participants were
within the age group of HPV vaccination recommen-
dation (i.e., 18–26 years) and eligible to remain on
their parent’s insurance plans. Nationally, 63% of
girls and 50% of boys have received at least one dose
of HPV vaccine and *33% completed the series.20
The HPV vaccination rate for our sampled population
was 7.3% (n = 14) for starting the series, 62.3% (n = 119)
for completing the vaccine series, and 3.1% (n = 6) for
not intending to complete the vaccine. Another small
percent/population, 4.2% (n = 8), reported not knowing
if they were vaccinated against HPV. Adolescent are
not always aware of which vaccine was received since
this is under the control of their parents’ consent, may
have been bundled with other required school-age vacci-
nations. Our completion rate is higher than the national
average. The vaccine is currently a two-dose regimen, a
shift from a three-dose regimen in 2016 offering protec-
tion to those not completing the HPV vaccine series. Spe-
cifically, a two-dose regimen is recommended for girls
and boys starting the HPV series at ages 9 through 14
years, and three doses remain for boys and girls starting
the HPV series at ages 15 through 26 years. Among our
study participants, vaccination rates were not separated
by gender; the study population was largely (85.6%)




or disagree Agree Strongly agree
n (%) n (%) n (%) n (%) n (%)
I do not believe in vaccinations generally. 176 122 (69.3) 39 (22.2) 11 (6.3) 3 (1.7) 1 (0.6)
Vaccinations are not effective and do not prevent diseases. 176 132 (75) 34 (19.3) 10 (5.7) 0 (0) 0 (0)
It is not important to receive all vaccinations. 176 101 (57.4) 42 (23.9) 17 (9.7) 8 (4.5) 8 (4.5)
It is preferable to get the diseases and be protected naturally than
to vaccinate.
176 118 (67.0) 40 (22.7) 16 (9.1) 1 (0.6) 1 (0.6)
I do not have confidence that the HPV vaccine is safe. 176 90 (51.1) 43 (24.4) 28 (15.9) 12 (6.8) 3 (1.7)
I believe if I receive the HPV vaccine, I will not be protected
from cervical cancer (anal/penile cancer if male).
175 71 (40.6) 56 (32.0) 35 (20) 11 (6.3) 2 (1.1)
I believe that if I receive the HPV vaccine, I will not be protected
against HPV.
176 80 (45.5) 63 (35.8) 23 (13.1) 6 (3.4) 4 (2.3)
I do not have enough information about HPV. 176 38 (21.6) 37 (21.0) 36 (20.5) 57 (32.4) 8 (4.5)
I do not have enough information about the HPV vaccine. 176 43 (24.4) 37 (21.0) 36 (20.5) 51 (29.0) 9 (5.1)
Cost would influence my uptake of the HPV vaccine. 176 54 (30.7) 40 (22.7) 28 (15.9) 39 (22.2) 15 (8.5)
My insurance/health care provider did not allow me to receive
the vaccine.
176 87 (49.4) 39 (22.2) 48 (27.3) 1 (0.6) 1 (0.6)
I did/do not have money for vaccination. 176 78 (44.3) 52 (29.5) 34 (19.3) 9 (5.1) 3 (1.7)
My sexual behavior is safe. 176 6 (3.4) 11 (6.3) 28 (15.9) 63 (35.8) 68 (38.6)
I do not believe that HPV is exceptionally harmful. 176 94 (53.4) 51 (29.0) 14 (8.0) 12 (6.8) 5 (2.8)






1. Safety/long-term side effects of the vaccine 22 10.5
2. Cost/vaccine not covered by health insurance 32 15.2
3. Vaccine is painful/discomfort with injection 13 6.2
4. Vaccine coverage (not preventing all HPV
strains or all STIs)
10 4.8
5. Not at risk or low risk for HPV 24 11.4
6. Not a priority 25 11.9
7. Access to health care provider 8 3.8
8. Embarrassed, self-conscious, or
uncomfortable talking to health care
provider
7 3.3
9. Lack of information and knowledge about HPV
or HPV vaccine
34 16.2
10. Parental influence in decision-making process
(i.e., mother/parents advised not to obtain
the vaccine)
23 11.0
11. Have already been diagnosed with HPV 7 3.3
12. Never had sexual intercourse 13 6.2
13. Current contraception practices are
sufficient for protection against HPV
3 1.4
14. Outside the recommended age group 14 6.7
15. Other 8 3.8
16. Not applicable, I already got the vaccine 104 49.5
Note: N = 210.
STI, sexually transmitted infection
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female. Knowledge with regard to required immunization
may be higher for college students due to vaccination
college entrance requirements.30 The American College
Health Association guidelines requirements for vaccine-
preventable diseases policy implementations found that
the immunization compliance rate among colleges were
about 93% among sampled colleges.30
This study occurred in a state with requirements for
some vaccination; Florida does no mandate HPV vac-
cination. A large majority of our sample (74%) of the
younger age group held the belief of HPV vaccine
being mandatory for children ages 9–12 years. This
majority also strongly disagreed with statements that
went against the importance of vaccinations. This
could be a positive predictor of support of childhood
vaccination for our future generation of parents.
Due to the immune system, HPV has a higher clear-
ance rate among younger age. But a greater propensity
for disease due to lower immune system has been
reported with increasing age. The small percentage of
7.1% reported ever having a positive HPV diagnosis sup-
ports national guidelines indicating that HPV screening
should not occur until age 30 years and above. The 26
years and older age group was more likely to agree
with the statement that HPV was not harmful. This find-
ing may indicate a need for greater health education re-
garding HPV and HPV vaccination. As reported in two
studies, there was a significant relationship between re-
ceiving health information through technology and age.
Younger study participants were more likely to want
HPV information through technology when compared
with older study participants.31,32 Digital health technol-
ogy can be cost effective and easily evaluated for effective-
ness in facilitating HPV knowledge and immunization
uptake. Opportunities to design age- and population-
specific education interventions has a role in digital tech-
nology health information dissemination.
Conclusion and Future Implications
Research findings supporting digital technology plat-
forms to disseminate evidence-based HPV data and
HPV vaccination educational information targeting ado-
lescents and young adults in academic and other setting
can help health care providers make informed decisions
about age-appropriate, topic, and content-relevant infor-
mation specifically targeting this population. The find-
ings of this study indicated that work is needed in the
acceptance of social media, SMS text messaging, and mo-
bile Apps as preferred digital health technologies beyond
the internet. Health care providers can educate parents
and students with regard to navigating the health system
to obtain health information by using text messages and
mobile apps, easily and effectively. Electronic health re-
cords, patient portals, and local health departments are
all possible repositories of vaccine information/status.
Taking advantage of patient encounters, such as annual
Well-Women Visits, provide opportune time to screen
for STDs, update vaccinations, and provide sexual and
reproductive health education. For example, Chlamydia
is the most common reportable STD in the United States.
HPV is the most common STD in women. Populations
most burdened by STDs are adolescents and young
adults ages 15–24 years. As per the CDC national guide-
lines, sexually active women under the age of 25 years
Table 6. Current Social Media Usage Trends Among College Students (N = 210)
Social media use Smartphone, n (%) Tablet, n (%) Computer, n (%) Do not use, n (%)
Facebook 159 (75.7) 42 (20%) 144 (68.6) 7 (3.3)
Instagram 142 (67.6) 15 (7.1) 24 (11.4) 26 (12.4)
LinkedIn 14 (6.7) 5 (2.4) 29 (13.8) 121 (57.6)
Pinterest 78 (37.1) 20 (9.5) 80 (38.1) 56 (26.7)
Twitter 70 (33.3) 11 (5.2) 31 (14.8) 86 (41.0)
Other 16 (7.6) 1 (0.5) 7 (3.3) 70 (33.3)
Note response range: several times a day, once a day, three times a week, 1–2 days a week, every few weeks, less often, I do not use.
Table 7. Current Social Media Visit Frequencies Among College Students
Frequency of visiting social media site Facebook, n (%) Instagram, n (%) LinkedIn, n (%) Pinterest, n (%) Twitter, n (%) Other, n (%)
Several times a day 124 (59) 113 (53.8) 1 (0.5) 17 (8.1) 34 (16.2) 12 (5.7)
About once per day 27 (12.9) 17 (8.1) 5 (2.4) 13 (6.2) 10 (4.8) 2 (1.0)
3–5 times a week 6 (2.9) 8 (3.8) 2 (1.0) 16 (7.6) 8 (3.8) 0 (0)
1–2 days a week 3 (1.4) 1 (0.5) 5 (2.4) 19 (9.0) 4 (1.9) 2 (1.0)
Every few weeks 2 (1.0) 3 (1.4) 12 (5.7) 25 (11.9) 8 (3.8 1 (0.5)
Less often 1 (0.5) 13 (6.2) 19 (9.0) 19 (9.0) 13 (6.2) 0 (0)
I do not use 7 (3.3) 30 (14.3) 123 (58.6) 58 (27.6) 88 (41.9) 107 (51)
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should be screened for gonorrhea, an opportune time to
discuss HPV and HPV vaccination.1 HPV testing is not
recommended in this age group, not until 30 years of
age.33 However, CDC, Association of American Cancer
Institutes, and American Cancer Society—leaders in
HPV cancer prevention—have partnered to establish
an HPV Vaccination Champion to reinforce that
HPV Vaccine is Cancer Prevention.34
The HPV Vaccination Roundtable is one such Vac-
cine Champion developing the campaign ‘‘We’re In!’’ a
Facebook profile picture frame.34 Facebook picture
frames are a way individuals can demonstrate support
for HPV vaccination as cancer prevention.34 Facebook
is one of many digital health platforms providing
evidence-based health information similar to Twitter,
Instagram, Google+, Vimeo, YouTube, Digg, Flikr, and
Pinterest. Internet or online websites are the preferred
digital health technologies for these study populations.
Growing evidence support using digital health technolo-
gies to inform decision making to increase HPV risk per-
ception and promote HPV vaccine uptake among
adolescents and young adults. Digital health technology
beyond the internet and online websites is warranted
and when used appropriately can be a strategic and suc-
cessful tool to inform decision making, increase percep-
tion, and promote HPV vaccine uptake. Text messaging
can be used to receive updates from healthcare providers.
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